ASAP — Asarina Pharma AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK1.09m
- -SEK1.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -886.74% | ||
| Return on Equity | -157.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
Directors
- Paul de Potocki CHM (56)
- Peter Nordkild CEO (63)
- Jakob Hansen CFO (63)
- Karin Ekberg COO (59)
- Torbjoern Baeckstroem CSO (73)
- Marta Segerdahl OTH (62)
- Otto Skolling OTH (58)
- Erin Gainer DRC (45)
- Miroslav Reljanovic DRC (63)
- Vidar Hansen IND (60)
- Marianne Kock IND (63)
- Mathieu Simon IND (65)
- Andre Ulmann IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 6th, 2006
- Public Since
- September 24th, 2018
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 22,641,409
- Address
- Karolinska Institutet Science Park, SOLNA, 171 65
- Web
- https://asarinapharma.com/
- Phone
- +46 852484482
- Contact
- Peter Nordkild
- Auditors
- Ernst & Young AB
Upcoming Events for ASAP
Similar to ASAP
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Asarina Pharma AB (publ) share price?
As of Today at 19:22 UTC, shares in Asarina Pharma AB (publ) are trading at SEK0.05. This share price information is delayed by 15 minutes.
How has the Asarina Pharma AB (publ) share price performed this year?
Shares in Asarina Pharma AB (publ) last closed at SEK0.05 and the price had moved by -94.86% over the past 365 days. In terms of relative price strength the Asarina Pharma AB (publ) share price has underperformed the FTSE Global All Cap Index by -95.59% over the past year.
What are the analyst and broker recommendations for Asarina Pharma AB (publ)?
The overall consensus recommendation for Asarina Pharma AB (publ) is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Asarina Pharma AB (publ) dividend yield?
Asarina Pharma AB (publ) does not currently pay a dividend.
Does Asarina Pharma AB (publ) pay a dividend?
Asarina Pharma AB (publ) does not currently pay a dividend.
When does Asarina Pharma AB (publ) next pay dividends?
Asarina Pharma AB (publ) does not currently pay a dividend.
How do I buy Asarina Pharma AB (publ) shares?
To buy shares in Asarina Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Asarina Pharma AB (publ)?
As of the previous close price of SEK0.05, shares in Asarina Pharma AB (publ) had a market capitalisation of SEK1.09m.
Where are Asarina Pharma AB (publ) shares listed?
Here are the trading details for Asarina Pharma AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ASAP
What kind of share is Asarina Pharma AB (publ)?
Based on an overall assessment of its quality, value and momentum Asarina Pharma AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Asarina Pharma AB (publ) share price forecast for 2024?
The analyst consensus target price for shares in Asarina Pharma AB (publ) is SEK17.00. That is 35316.67% above the last closing price of SEK0.05.
Analysts covering Asarina Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Asarina Pharma AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Asarina Pharma AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -94.83%.
As of the last closing price of SEK0.05, shares in Asarina Pharma AB (publ) were trading -93.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Asarina Pharma AB (publ) PE Ratio?
The Asarina Pharma AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Asarina Pharma AB (publ)?
Asarina Pharma AB (publ)'s management team is headed by:
- Paul de Potocki - CHM
- Peter Nordkild - CEO
- Jakob Hansen - CFO
- Karin Ekberg - COO
- Torbjoern Baeckstroem - CSO
- Marta Segerdahl - OTH
- Otto Skolling - OTH
- Erin Gainer - DRC
- Miroslav Reljanovic - DRC
- Vidar Hansen - IND
- Marianne Kock - IND
- Mathieu Simon - IND
- Andre Ulmann - IND